# A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer

> **NCT00398567** · PHASE1,PHASE2 · COMPLETED · sponsor: **Puma Biotechnology, Inc.** · enrollment: 45 (actual)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** HKI-272
- **DRUG:** trastuzumab

## Key facts

- **NCT ID:** NCT00398567
- **Lead sponsor:** Puma Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04-04
- **Primary completion:** 2009-07-31
- **Final completion:** 2018-03-02
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2018-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00398567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00398567, "A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00398567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*